Amgen Showcases Oncology Pipeline At ASCO 2019

Data From Largest Oncology Pipeline in Company's History First-in-Human Data Evaluating Investigational AMG 510, the First KRASG12C Inhibitor to Reach Clinical Stage, in Solid Tumors Potential Versatility of BiTE® Immuno-oncology Platform Reinforced With Phase 1 Asset Updates THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors. "Biology and human genetics have been the foundati...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news